Related Experiment Video

Updated: May 29, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis

Fei Xu1, Ying Tian, Yan Huang

  • 1State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, People's Republic of China.

Chinese Journal of Cancer
|October 1, 2011
PubMed

Insights

Combining tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy with epidermal growth factor receptor (EGFR) inhibitors enhances anti-tumor activity in non-small cell lung cancer (NSCLC). This combination therapy effectively reduces tumor growth and promotes apoptosis by modulating key cellular pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Apoptosis, a programmed cell death process, can be triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
  • The epidermal growth factor (EGF) signaling pathway, often dysregulated in cancer, can influence TRAIL-induced apoptosis.
  • Non-small cell lung cancer (NSCLC) remains a significant health challenge, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To investigate the combined antitumor effects of recombinant adenoviral vectors encoding TRAIL (AdTRAIL) and epidermal growth factor receptor (EGFR) inhibitors in NSCLC.
  • To elucidate the molecular mechanisms underlying the enhanced anti-tumor activity of this combination therapy.

Main Methods:

  • Utilized recombinant adenoviral vectors (AdTRAIL) expressing the TRAIL gene under the hTERT/RGD promoter.
  • Administered AdTRAIL in combination with EGFR inhibitors (gefitinib, erlotinib, cetuximab) to NSCLC cell lines (H460, A549, SW1573) in vitro.
  • Evaluated tumor growth inhibition using H460 xenografts in nude mice, combined with histological and TUNEL analyses.

Main Results:

  • Combination therapy of AdTRAIL and EGFR inhibitors significantly reduced proliferation and enhanced apoptosis in NSCLC cell lines compared to single agents.
  • Western blot analysis revealed that the combination therapy led to increased BAX (pro-apoptosis) and decreased p-AKT (survival signaling) protein levels.
  • In vivo studies demonstrated that AdTRAIL combined with cetuximab significantly inhibited H460 xenograft growth without causing major organ damage.

Conclusions:

  • EGFR inhibitors potentiate the anti-tumor efficacy of AdTRAIL in NSCLC.
  • Inhibition of the AKT signaling pathway is a key mechanism contributing to the enhanced apoptosis observed with the combination therapy.
  • This combined therapeutic approach holds promise for the treatment of non-small cell lung cancer.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...